Stock Analysis
InnoCan Pharma Third Quarter 2024 Earnings: US$0.001 loss per share (vs US$0.008 loss in 3Q 2023)
InnoCan Pharma (CSE:INNO) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$8.62m (up 111% from 3Q 2023).
- Net loss: US$290.0k (loss narrowed by 86% from 3Q 2023).
- US$0.001 loss per share (improved from US$0.008 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
InnoCan Pharma shares are down 2.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - InnoCan Pharma has 2 warning signs we think you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:INNO
InnoCan Pharma
A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
